Hemophilia Disease Management

Why the Program Matters

Hemophilia is a hereditary blood disorder that is life-long and has very high costs to treat. A patient with a moderate condition faces average annual expenses of $200,000 to $300,000. For a patient with a severe case, the cost can be $500,000 or more. The main driver of these expenses is the cost of the blood factor products that hemophilia patients need to prevent terminal bleeding.

How the Program Works

In collaboration with the Indiana Hemophilia and Thrombosis Center (IHTC), 55 Hemophilia patients that were high-risk were placed in a specialized IHTC disease management program and all patient care was coordinated with IHTC providers. The goal of the Hemophilia program is to improve healthcare outcomes and reduce costs for people with Hemophilia and blood related disorders.

The individualized Disease Management plans of the IHTC focus on clinical techniques and rely on intensive commitments from hemophilia care providers, patients, and patient families. Patients and their families work closely with experts in hemophilia care to learn how best to manage the disorder. The results ware better patient care at a significantly reduced cost.

The IHTC is a federally recognized comprehensive center with program staff members dedicated to the care of patients with hemophilia. The comprehensive center’s hematologist(s) and staff spend a significant amount of time specifically caring for hemophilia patients. The IHTC’s integrated, focused approach results in the best care and lowest morbidity for the patients who are enrolled into the program.

Program Results Overview

During the first four years of active program management, the Hemophilia program reduced overall expenses and improved health care outcomes for 55 hemophilia patients in Indiana, saving more than $16 million over four years. This was accomplished by reducing the cost of blood factor products and working with each individual on a Disease Management (DM) plan tailored to that person’s needs.

Overall costs were lowered through improved patient knowledge and shared commitment of all partners including state and federal agencies and insurance programs.

hemophilia-results-infographic